ADAM17 inhibition enhances platinum efficiency in ovarian cancer

Chemotherapeutic resistance evolves in about 70 % of ovarian cancer patients and is a major cause of death in this tumor entity. Novel approaches to overcome these therapeutic limitations are therefore highly warranted. A disintegrin and metalloprotease 17 (ADAM17) is highly expressed in ovarian can...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedemann, Nina, Rogmans, Christoph, Sebens, Susanne, Wesch, Daniela, Reichert, Manuel, Schmidt-Arras, Dirk, Oberg, Hans-Heinrich, Pecks, Ulrich, van Mackelenbergh, Marion, Weimer, Jörg, Arnold, Norbert, Maass, Nicolai, Bauerschlag, Dirk O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882316/
https://www.ncbi.nlm.nih.gov/pubmed/29662625
http://dx.doi.org/10.18632/oncotarget.24682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882316/
https://www.ncbi.nlm.nih.gov/pubmed/29662625
http://dx.doi.org/10.18632/oncotarget.24682

Ejemplares similares